Phase II study of ifosfamide+doxorubicin in patients with advanced synovial sarcomas (E1793): A trial of the Eastern Cooperative Oncology Group

Publication Type:
Journal Article
Citation:
Sarcoma, 2003, 7 (1), pp. 9 - 11
Issue Date:
2003-03-01
Metrics:
Full metadata record
Files in This Item:
Filename Description Size
Thumbnail2012000880OK.pdf52.39 kB
Adobe PDF
Purpose: Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) decided to further assess this two drug combination in a subsequent Phase II study. Patients: Between 1994 and 1999, twelve adult patients with advanced synovial sarcomas were enrolled to receive, as their initial chemotherapy, ifosfamide 7.5 gm/m2plus doxorubicin 60 mg/m2, given intravenously over two consecutive days every 3 weeks. Methods: Each day for 2 days doxorubicin 30 mg/m2was infused over 5 min through a running i.v., followed by ifosfamide 3750 mg/m2over 4h. Continuous i.v. fluid was infused at 300 mL/h for 3h on day 1, before chemotherapy was begun; then the infusion was continued at 100 mL/h for a total of 3 days. Mesna 750 mg/m2was given 15 min before ifosfamide and at 4 and 8h after ifosfamide on days 1 and 2 of each treatment cycle. Filgrastim (G-CSF) 5 μg/kg was given subcutaneously each day for 14 days beginning on day 3 of each treatment cycle to limit the severity of neutropenia. Results: Five of our 12 patients (42%) experienced partial regression of their advanced synovial sarcomas; however, this first stage result was borderline for proceeding to the second planned stage of accrual and our case accrual was quite poor. Thus, the study was closed after stage one accrual. Our patients received a median of four cycles of chemotherapy (range: 1 to 6). All patients experienced at least grade 3 neutropenia (grade 4 in nine of them), and one patient died of treatment-related sepsis following the initial cycle of chemotherapy. Median survival was 11 months.
Please use this identifier to cite or link to this item: